By Aditi Pai
Read the original article here: MobiHealthNews
###
New York City-based Force Therapeutics raised $1.7 million in a round that the company started September 2013, according to an SEC filing. This brings the company's total funding to date to $2.2 million.
Existing investors include former OpenTable CEO Thomas Layton; former CEO of Revolution Health and TicketMaster, John Pleasants; and FiveW Capital Managing Member Randall Winn. The company raised its seed round after graduating from StartUp Health.
Force Therapeutics has developed a mobile and web-based program that can be prescribed to patients who are taking part in musculoskeletal injury rehabilitation by their surgeon, physician, or therapist.
New York City-based Force Therapeutics raised $1.7 million in a round that the company started September 2013, according to an SEC filing. This brings the company's total funding to date to $2.2 million.
Existing investors include former OpenTable CEO Thomas Layton; former CEO of Revolution Health and TicketMaster, John Pleasants; and FiveW Capital Managing Member Randall Winn. The company raised its seed round after graduating from StartUp Health.
Force Therapeutics has developed a mobile and web-based program that can be prescribed to patients who are taking part in musculoskeletal injury rehabilitation by their surgeon, physician, or therapist.
"The home has become a focal point of value-based care delivery," the company explains in a video. "Force is taking this vision and allowing providers to make the home a meaningful, valuable, and profitable component of their evolving care continuum."
The app, called Force Patient, which is available on iOS and Android devices, helps patients access home exercise videos, log their compliance, read educational materials, purchase recommended gear, and receive messages from their care team. Providers can use the program to view a patient's compliance, activity levels, and outcomes.
Force Theraputics CEO and cofounder Bronwyn Spira is a physical therapist and the company's president, Mark Lieberman, was previously at Merck and biopharmaceutical company Imclone Systems.